Seattle Times -- Bristol-Myers Squibb, which bought Seattle drugmaker ZymoGenetics last year, plans to keep a long-term presence in Seattle's South Lake Union district, a spokeswoman said late Tuesday.
Seattle Times -- Bristol-Myers Squibb, which bought Seattle drugmaker ZymoGenetics last year, plans to keep a long-term presence in Seattle's South Lake Union district, a spokeswoman said late Tuesday.
